Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-354-6 | CAS number: 106-02-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
Table 7.6/1: Summary of genotoxicity tests
Test n° |
Test / Guideline Reliability |
Focus |
Strains / cells tested |
Metabolic activation |
Test concentration |
Statement |
1
Tzan King, 2001 |
Ames Test (OECD 471) K, rel. 1 |
Gene mutation |
TA 1535 TA 1537 TA 98 TA 100 TA 102 |
-S9 +S9 |
Up to 5000 µg/plate |
-S9 : non mutagenic +S9 : non mutagenic |
2
Abramsson, 2002 |
Ames Test S, rel. 4 |
Gene mutation |
TA 97 TA 98 TA 100 |
-S9 +S9 |
Up to 1300 µg/plate |
-S9 : non mutagenic +S9 : non mutagenic |
3 (RA)
Thompson, 2005 |
Ames Test (OECD 471) S, rel. 2 |
Gene mutation |
TA 1535 TA 1537 TA 98 TA 100 WP2 uvrA |
-S9 +S9 |
Up to 5000 µg/plate |
-S9 : non mutagenic +S9 : non mutagenic |
4 (RA)
Sokolowski, 2005 |
Ames Test (OECD 471) S, rel. 2 |
Gene mutation |
TA 1535 TA 1537 TA 98 TA 100 TA 102 |
-S9 +S9 |
Up to 5000 µg/plate |
-S9 : non mutagenic +S9 : non mutagenic |
5 (RA)
Durward & Nolan, 2001 |
ML/TK test (OECD 476) K, rel. 2 |
Gene mutation |
mouse lymphoma L5178Y cells |
-S9 +S9 |
Up to cytotoxic concentration |
-S9 : non mutagenic +S9 : non mutagenic |
6
Abramsson, 2002 |
In vivo micronucleus (eq. OECD 474) WoE, rel. 2 |
Chromosomal aberration |
PCE from peripheral blood |
n.a. |
M: Up to 1600 mg/kg bw/d F: Up to 1400 mg/kg bw/d |
Non clastogenic, non aneugenic |
7 (RA)
Schulz, 2005 |
HL CAT (OECD 473) WoE, rel. 2 |
Chromosomal aberration |
Human Lymphocytes |
-S9 +S9 |
Up to cytotoxic concentrations (-S9) or precipitating concentrations (+S9) |
-S9 : non clastogenic +S9 : non clastogenic |
8 (RA)
Durward, 1995 |
HL CAT (OECD 473) WoE, rel. 2 |
Chromosomal aberration |
Human Lymphocytes |
-S9 +S9 |
Up cytotoxic concentrations |
-S9 : non clastogenic +S9 : non clastogenic |
Gene mutation Assays (Tests n° 1-5):
Two Bacterial Reverse mutation Assays (Ames test) were conducted with the substance (See Table 1). Test n°1, conducted according to OECD test guideline No 471 and in compliance with GLP, was selected as the key study. Test 2 was used as supporting data because only three strains of bacteria were used. No significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains in both tests, with any dose of the test material, either with or without metabolic activation. Both tests indicate that the substance does not induce gene mutations in bacteria whereas all positive control chemicals (with and without metabolic activation) induced significant increase of colonies. This result is also supported by two Ames tests, conducted on the supporting substance (EC 422 -320 -3) (Test n°3 and 4, see Iuclid Section 13 for read-across justification). The substance is therefore considered as non-mutagenic according to the Ames test.
Inability to produce gene mutation was confirmed in mammals using an in vitro forward mutation assay in mouse lymphoma TK L5178Y cells (ML/TK test) (Test n°5) conducted on the supporting substance (EC 422 -320 -3). None of the dose levels up to the cytotoxicity limit, either with or without metabolic activation, induced significant mutant frequency increases in the initial or repeat tests. The supporting substance (EC 422 -320 -3) does not induce forward mutations at the TK locus in L5l78Y mouse lymphoma cells under activation and non-activation conditions whereas both positive control chemicals (with and without metabolic activation) induced significant mutant frequency increases. The supporting substance (EC 422 -320 -3) is therefore considered as negative for inducing forward mutations at the TK locus in L5178Y mouse lymphoma cells under activation and non-activation conditions used in this assay. This result confirms the results of the Ames tests and extends the non-mutagenic effect of the substance to mammalian cells.
Chromosomal aberration (Test n°6-8)
The clastogenic and aneugenic potential of the substance was determined using an in vivo mammalian erythrocytes micronucleus assay (Test n°6), which measured the potential of a substance to increase the incidence of the structural and numerical chromosome aberrations in mice bone marrow erythrocytes. None of the dose level, up to the dose of 1600 mg/kg bw in males or 1400 mg/kg bw in females, induced increase in the frequency of micronucleated polychromatic erythrocytes (fMPCE) in bone marrow, whereas positive control chemical induced significant increase in the fMPCE. The substance was therefore considered as negative for inducing chromosomal aberrations in mice bone marrow erythrocytes under the conditions used in this study. This result is also supported by two in vitro chromosome aberration tests in Chinese hamster lung fibroblast, conducted on the supporting substance (EC 422 -320 -3) (Test n°7 and 8). In both tests, none of the dose levels up to the cytotoxicity or precipitating limit, either in the presence of absence of metabolic activation, induced significant increases in the frequency of cells with aberrations.
The substance is therefore considered as non-clastogenic and non-aneugenic.
Justification for selection of genetic toxicity endpoint
No study was selected since all the studies were negative.
Short description of key information:
- Ames Test (OECD 471, GLP, K, rel. 1): non mutagenic up to cytotoxic concentrations in S. typhimurium TA 1535, TA 1537, TA 98, TA 100, and TA102.
- MLA/TK Forward Mutation Assay with a Confirmatory Assay (OECD 476, GLP, K, rel. 2): non mutagenic up to cytotoxicity limit on the supporting substance.
- In vivo micronucleus (eq. OECD 474, WoE rel. 2): no increased in MPCE + Human lymphocyte chromosome aberration test (OECD 473, GLP, WoE, rel. 2): non clastogenic up to cytotoxic limit / precipitating concentration on the supporting substance.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Harmonized classification:
The substance has no harmonized classification for human health according to the Regulation (EC) No. 1272/2008 including the ATP3.
Self classification:
Based on the available information, no additional classification is proposed according to the Annex VI of the Regulation (EC) No. 1272/2008 (CLP) and of the Directive 67/548/EEC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.